EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC 3.0

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Stephanie M Barrows, Kelly Wright, Catherine Copley-Merriman, James A Kaye, Marc Chioda, Robin Wiltshire, Knut Martin Torgersen, Elizabeth T Masters

Lung Cancer: Targets and Therapy · 2019-02 · Volume 10 · 11-20

DOI: 10.2147/lctt.s179349 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2019-02. Verfasst von Stephanie M Barrows und 7 weiteren Autor:innen. Beteiligte Einrichtung: Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4-89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5-22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.

Schlagwörter

Stichwörter der Autor:innen

ALKNSCLCcarcinomanon-small-cell lungnon-small-cell lung cancer

Autor:innen und Institutionen

  • Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.
  • Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA.
  • Medical Affairs, Pfizer, Inc., New York, NY, USA.
  • Medical Affairs, Pfizer Limited, Walton Oaks, UK.
  • Medical Affairs, Pfizer, Inc., Oslo, Norway.
  • Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA.

Zitieren

APA

Barrows, S. M., Wright, K., Copley-Merriman, C., Kaye, J. A., Chioda, M., Wiltshire, R., Torgersen, K. M., & Masters, E. T. (2019). Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer: Targets and Therapy, Volume 10, 11-20. https://doi.org/10.2147/lctt.s179349

Vancouver

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, et al. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer: Targets and Therapy. 2019;Volume 10:11-20. doi:10.2147/lctt.s179349

BibTeX
@article{Barrows2019,
  author = {Barrows, Stephanie M and Wright, Kelly and Copley-Merriman, Catherine and Kaye, James A and Chioda, Marc and Wiltshire, Robin and Torgersen, Knut Martin and Masters, Elizabeth T},
  title = {Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer},
  journal = {Lung Cancer: Targets and Therapy},
  year = {2019},
  volume = {Volume 10},
  pages = {11--20},
  doi = {10.2147/lctt.s179349}
}
Kostenlos starten →